000000427185 Robert K. Andrews, PhD		Associate Editor	Last Confirme	ed Date:
Company:	Relationship:	Additional Inf	Cormation	End Date
Blood journal	Honoraria	Associate Edito	or of Blood	
Monash University	Employment	Associate Profe Research Appo	*	12/31/2019
National Health and Medical Research Council of Australia	Research Funding	Project grant		12/31/2019
Research Advisory Committee of the Australian Red Cross Blood Service	Membership on a Board of Advisory Committee	or Member of the Advisory Com	11000001011	

000000428364	Herve Avet Loiseau, MD, PhD	Associate Editor	Last Confi	med Date: 02/05/2018
Company:	Relationship:	Additional In	nformation	End Date
Amgen	Membership on a B Advisory Committe			
Amgen	Research Funding			
Celgene	Membership on a B Advisory Committe			
Celgene	Research Funding			
Janssen-Cilag	Membership on a Book Advisory Committee			01/01/2019
Janssen-Cilag	Research Funding			

000000123461	Nancy Berliner, MD		Editor		Last Confirmed Da	te: 02/04/2019
Company:		Relationship:		Additional Informa	tion	End Date
Clinical Decision S	Support	Patents & Royalties		On-line clinical supp currently an Associat Editor. Program is in development. We have received nNo royalti- date.	te 1 ve	
Novartis		Research Funding		Research funding for preclinical and clinic transferred to me as the departure of one junior faculty.	eal trials PI upon	01/01/2019
Up To Date		Honoraria		Author for UpToDate Receive honoraria for updating chapters.		

000000427017	Catherine M. Bollard, MD, MBChB	Associate Editor	Last Confirm	ed Date: 12/11/2019
Company:	Relationship:	Additional Inf	· Cormation	End Date
	Nothing to disclose.			01/25/2018
Caballeta Bio	Equity Ownership	Stock options		
Caballeta Bio	Membership on a Boar Advisory Committee	d or Member of the Directors with		
Cellectis	Honoraria			
Cellectis	Membership on a Boar Advisory Committee	d or		
Mana Therapeutics	Equity Ownership			01/01/2039
Mana Therapeutics	Membership on a Boar Advisory Committee	d or Serve on Scien Board	tific Advisory	01/01/2039
Mana Therapeutics	Patents & Royalties			01/01/2039
Neximmune	Equity Ownership	Own stock		
Neximmune	Honoraria			12/01/2018
Neximmune	Membership on a Boar Advisory Committee	d or		12/01/2018
Torque	Equity Ownership	Stock		
Torque	Honoraria			12/01/2018
Torque	Membership on a Boar Advisory Committee	d or		12/01/2018

000000123418	Mario Cazzola, MD		Associate Editor	Last Confirmed Da	ite: 12/16/2019
Company:		Relationship:	Additional Informa	ation	End Date
		Nothing to disclose.			
		Nothing to disclose.			01/29/2018
Incyte Corporation	n	Membership on a Board or Advisory Committee	r		

000000122721	Thomas D. Coates, MD	Associate Editor	Last Confirm	Confirmed Date: 02/06/2018	
Company:	Relationship:	Additional Inf	ormation	End Date	
Alnylam Pharma	Consultancy	consult RE hep regulator	cidin	01/01/2019	
Apo Pharma	Consultancy	Consult regardi neutropenia and management	~	01/01/2019	
Apo Pharma	Honoraria	Speak at educat meetings on iro management		01/01/2019	
Apo Pharma	Membership on a Bo Advisory Committee	1	enia advisory	01/01/2019	
Celgene	Consultancy	have done advi- past	sory board in	01/01/2019	
Celgene	Research Funding	PI on two phase trials for Celger thalassemia.		01/01/2021	
Prolong PHarma	Consultancy	consult regardii of sickle cell di	~	01/01/2019	
Sangamo	Consultancy	DMC Re gene	therapy trial	01/01/2019	
UpToDate	Patents & Royalties	Receive royalti chapters writter Date		01/01/2019	
Vifor Pharma	Consultancy	Consult regardi hepcidin regula	~	01/01/2019	

000000425519 John D. Crispino, PhD, MBA		ociate Editor Last Confirm	Last Confirmed Date: 02/08/2019	
Company:	Relationship:	Additional Information	End Date	
	Nothing to disclose.		01/11/2019	
	Consultancy	Consultant for the Imetelstat program	01/01/2037	
Forma Therapeutics	Research Funding	Forma funds research to assess the activity of a new bromodomain inhibitor in pre-clinical assays.	12/31/2019	
MPN Research Foundation	Membership on a Board or Advisory Committee	I am a paid Scientific Advisor for this non-profit patient advocacy foundation.		
Scholar Rock	Research Funding	Scholar Rock funds research to assess a new TGF-beta inhibitor in pre-clinical studies.	12/31/2019	
Sierra Oncology	Consultancy	Provide consultation on pre-clinical studies of the Jak inhibitor momelotinib.	12/31/2019	

000000427430	Herve Dombret, MD		Associate Editor	Last Confirmed Date:	
Company:		Relationship:	Additional Informa	tion End	d Date
BMS	I	Honoraria	Lecture fees		
BMS		Membership on a Board of Advisory Committee	or Paid advisory boards	3	
Celgene]	Honoraria	Lecture fees		
Celgene		Membership on a Board o Advisory Committee	or Paid advisory boards	3	
Chugai Sanofi Av	entis (Consultancy	Paid expert reports		
Genzyme]	Honoraria	Lecture fees		
Genzyme		Membership on a Board o Advisory Committee	or Paid advisory boards	3	
Novartis	I	Honoraria	Lecture fees		

000000124273	Michael J. Hallek, MD	Associate Editor	Last Confirm	ed Date:
Company:	Relationship:	Additional In	formation	End Date
Gilead	Honoraria	occasional ad	boards	
Gilead	Research Funding	participation is	n a clinical tria	
Mundipharma	Research Funding			01/01/2021
Mundipharma	Speakers Bureau			
Roche	Consultancy			
Roche	Honoraria			
Roche	Research Funding			

000000126615	Jose A. Lopez, MD, BS	Associate Editor	Last Confir	med Date: 01/09/2019
Company:	Relationship:	Additional In	formation	End Date
	Nothing to disclose.			

000000125037	Selina Luger, MD, FRCPC	Associate Editor	Last Confirmed Date: 08/01/2019	
Company:	Relationship:	Additional Infor	mation	End Date
agios	Honoraria			12/10/2020
Ariad	Research Funding			
Biosight	Research Funding	to institution		
Celgene	Research Funding			
Cyclacel	Research Funding			
Daichi Sankyo	Honoraria			04/15/2019
genentech	Research Funding	clinical trial fundi institution	ng to	
Jazz	Honoraria			12/10/2018
kura	Research Funding			
Onconova	Research Funding	Clinical Trial, sit	e PI	01/01/2021
pfizer	Honoraria			
Seattle Genetics	Research Funding			

000000126102 Thomas L. Ortel, MD, PhD		sociate Editor L	Last Confirmed Date: 02/14/2019	
Company:	Relationship:	Additional Information	on End Date	
Instrumentation Laboratory	Consultancy	Provide recommendaticoncerning hemostasis testing.	* * * *	
Instrumentation Laboratory	Research Funding	Research support	01/01/2020	
Siemens	Research Funding		01/01/2020	
Up To Date	Membership on a Board or Advisory Committee	Write sections on anticoagulant therapy i patients with infectious endocarditis and diagnand treatment of antiphospholipid syndr	s osis	

000000428601 Andrew W. Roberts, MBBS		eputy Editor Last Confi	Last Confirmed Date: 12/05/2019	
Company:	Relationship:	Additional Information	End Date	
Abbott	Research Funding			
AbbVie	Patents & Royalties	My employer, the Walter and Eliza Hall Institute receives milestone and royalty payments from Genentech and AbbVie for the development of ABT-199. Under the Institute's commercialization policy, I am eligible to receive a small fraction of these royalties (from Oct 2018).	01/01/2034	
Abbvie (formerly Abbott)	Patents & Royalties	My employer, the Walter and Eliza Hall Institute receives milestone and royalty payments from Genentech and AbbVie for the development of ABT-199. Under the Institute's commercialization policy, I am eligible to receive and do receive a fraction of these royalties (from Oct 2018).	01/01/2034	
Australasian Leukaemia and Lymphoma Group	Membership on a Board or Advisory Committee	Not for profit National Clinical Trials Consortium		
Australasian Leukaemia and Lymphoma Group	Membership on a Board or Advisory Committee	Not-for-profit Australian and New Zealand Clinical Trials Group	01/01/2020	
Cancer Council of Victoria	Membership on a Board or Advisory Committee	Member of Medical and Scientific Advisory Committee	01/01/2020	
Genentech	Patents & Royalties	Not for profit organisation - State Employee of Walter and Eliz Hall Institute which receives milestone payments relating to ABT-199		

Genentech Patents & Royalties My employer, the Walter 01/01/2034 and Eliza Hall Institute receives milestone and royalty payments from Genentech and AbbVie for the development of ABT-199. Under the Institute's commercialization policy, I am eligible to receive and do receive a fraction of these royalties (from Oct 2018). Genentech Research Funding Research Funding Janssen Funding for an investigator 01/01/2019 initiated clinical trial. Paid to institution Research Funding Servier Laboratory research funding for specific contract research

000000127348	Irene Roberts, MD		Associate Editor	Last Confir	Confirmed Date: 02/21/2019	
Company:		Relationship:	Additional Information		End Date	
		Nothing to disclose.				
		Nothing to disclose.				

000001000431	Laurie Sehn, MD, MPH	Associate Editor	Last Confir	Last Confirmed Date: 02/26/2019	
Company:	Relationship:	Additional Inf	formation	End Date	
	Consultancy			01/01/2037	
	Consultancy			01/01/2038	
	Honoraria			01/01/2037	
	Honoraria			01/01/2037	
	Honoraria			01/01/2038	
	Honoraria	Honoraria		01/01/2038	
	Membership on a Boar Advisory Committee Research Funding	rd or		01/01/2038 01/01/2038	
Abbvie	Honoraria				
Acerta	Consultancy				
Acerta	Honoraria				
Amgen	Consultancy				
Amgen	Honoraria				
apobiologix	Consultancy				
apobiologix	Honoraria				
Astra Zeneca	Consultancy				
Astra Zeneca	Honoraria				
Celgene	Honoraria				
Gilead	Consultancy				
Gilead	Honoraria				
Janssen	Honoraria				
Karyopharm	Consultancy				
Karyopharm	Honoraria				
Kite	Consultancy				
Kite	Honoraria				
Lundbeck	Honoraria				
Merck	Consultancy				
Merck	Honoraria				
Morphosys	Consultancy				
Morphosys	Honoraria				
Roche/Genentech					
Roche/Genentech	Honoraria				

Roche/Genentech Honoraria 01/01/2019

Roche/Genentech Research Funding

Seattle Genetics Honoraria 01/01/2019

Takeda Consultancy
Takeda Honoraria
Teva Consultancy
Teva Honoraria
TG Therapeutics Consultancy
TG Therapeutics Honoraria

000001089568 Freda K. Stevenson, DPhil Associate Editor Last Confirmed Date: 02/10/2019

Company: Relationship: Additional Information End Date

Nothing to disclose.

Nothing to disclose. Nothing to disclose.

000001005668	Robert Zeiser, MD		Associate Editor	Last Confirme	d Date: 12/28/2019
Company:		Relationship:	Additional Info	ormation	End Date
		Nothing to disclose.			
Jazz Pharmaceution	cals	Research Funding	Financial supporesearch project		02/28/2018
Mallinckroth		Honoraria			
Novartis		Research Funding			09/01/2019